截至2025年9月19日收盘，联影医疗(688271)报收于147.9元，下跌1.4%，换手率0.82%，成交量6.74万 手，成交额10.05亿元。 当日关注点 交易信息汇总资金流向 9月19日主力资金净流出9037.99万元，占总成交额8.99%；游资资金净流入4796.37万元，占总成交额 4.77%；散户资金净流入4241.62万元，占总成交额4.22%。 公司公告汇总 上海联影医疗科技股份有限公司2025年半年度持续督导跟踪报告 中信证券和中金公司作为联影医疗的保荐人，出具2025年半年度持续督导跟踪报告。报告期内，公司未 发现重大问题及重大违规事项，核心竞争力未发生重大不利变化。公司实现营业收入60.16亿元，同比 增长12.79%；归母净利润9.98亿元，同比增长5.03%；扣非归母净利润9.66亿元，同比增长21.01%。海 外收入达11.42亿元，同比增长22.48%。研发投入合计11.40亿元，资本化研发投入同比增加95.56%。公 司持续加大研发，多个项目取得注册证。募集资金使用合规，控股股东及实控人持股未变，部分高管因 个人资金需求减持间接持股。 以上内容为证券之星据公开信息整理，由A ...

证券日报网讯 爱迪特8月27日发布公告，在公司回答调研者提问时表示，公司2025年上半年研发投入同 比增长36%，在关键领域目前公司在新材料、数字化设备、软件方面均有在研技术和产品，比如3D打 印智能机、窄颈种植系统、树脂渗透陶瓷等，旨在提升公司在种植、正畸领域的竞争力。 （编辑 袁冠琳） ...

Core Viewpoint - Shanghai Pharmaceuticals is expected to significantly enhance its profitability due to the acquisition of a 10% stake in Shanghai Hutchison Pharmaceuticals, leading to a projected net profit of 44.50 billion yuan for the first half of 2025, representing a year-on-year increase of approximately 52% [2][3]. Financial Performance - The company anticipates a net profit of 44.50 billion yuan for the first half of 2025, an increase of 15.08 billion yuan compared to the previous year [3]. - In 2024, Shanghai Pharmaceuticals achieved a revenue of 2,752.51 billion yuan, a year-on-year growth of 5.75%, and a net profit of 45.53 billion yuan, up 20.82% [5]. - The net profit for the first quarter of 2025 was reported at 13.33 billion yuan, reflecting a decline of 13.56% year-on-year, which was reversed by the recent acquisition [4]. Cost Management - The company has successfully reduced sales expenses for two consecutive years, with a 16.11% decrease in the first quarter of 2025 [8][7]. - Sales expenses for 2023 and 2024 were 139.02 billion yuan and 127.14 billion yuan, respectively, showing a decline of 2.64% and 8.55% year-on-year [7]. R&D Investment - Research and development expenses have been on the rise for three consecutive years, with amounts of 21.12 billion yuan, 22.04 billion yuan, and 23.94 billion yuan from 2022 to 2024, reflecting growth rates of 6.29%, 4.35%, and 8.64% respectively [9]. - In the first quarter of 2025, R&D expenses were 4.97 billion yuan, showing a slight decrease of 0.88% year-on-year [10]. Shareholder Confidence - The controlling shareholder, Shanghai Industrial Group, has increased its stake in Shanghai Pharmaceuticals by 1.995%, reflecting confidence in the company's future development [2][11]. - The total shares held by Shanghai Industrial Group after the increase amount to 1.426 billion shares, representing approximately 38.461% of the total issued shares [12]. Dividend History - Since its listing, Shanghai Pharmaceuticals has distributed dividends 30 times, totaling 157.46 billion yuan, with 114.14 billion yuan from A-shares and 43.32 billion yuan from H-shares [12].